Prostate cancer

Studies Presented at AUA 2024 Highlight Latest Research on Voiding Dysfunction and BPH

Retrieved on: 
Saturday, May 4, 2024
Dementia, Prostate cancer, Albany Medical College, Abstract, Woman, MD, Research, Division

Researchers will present their study findings covering important updates on sexual function in San Antonio, TX, from May 3 to 6.

Key Points: 
  • Researchers will present their study findings covering important updates on sexual function in San Antonio, TX, from May 3 to 6.
  • Charles Welliver, MD, director of men’s health in the Division of Urology at Albany Medical College, moderated a virtual press session with the abstract authors, providing key insights into their research.
  • “In this panel we talk about very common problems that affect all men and women throughout the United States,” said Dr. Welliver “We look at a variety of high yield interesting questions about both prostate cancer prevention to dementia risks associated with medications.”
    The following abstracts are covered in the moderated panel:

Studies Indicate Environmental Factors Can Impact Urologic Health

Retrieved on: 
Friday, May 3, 2024
Population health, Drinking water, Risk, Tissue, Pesticide, American Urological Association, Abstract (summary), Abstract, NYU Langone Health, Fertility, Research, Prostate cancer, Urology, Bladder cancer, SAN, Agriculture

Researchers will present environmental and urological health study findings in San Antonio, Texas, from May 3 to 6.

Key Points: 
  • Researchers will present environmental and urological health study findings in San Antonio, Texas, from May 3 to 6.
  • Stacy Loeb, MD, Urology and Population Health professor at NYU Langone Health, moderated a virtual press session with the abstract authors, providing key insights into their research.
  • “It’s great that these studies are happening so we can get a better sense of how some of these environmental factors may affect things like fertility and urological cancer risk,” said Dr. Loeb.
  • It sounds like, in these cases, more studies are needed to follow up on these findings on an individual level.”
    The following abstracts are covered in the moderated panel:

Phase 2 data for ERLEADA® (apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localized prostate cancer show 100% biochemical free recurrence rate more than two years post-surgery

Retrieved on: 
Friday, May 3, 2024
BCR, RP, Risk, Johnson & Johnson, Recurrence, ADT, Research, Abstract, Prostate cancer, Disease, Patient, Urology, Neoplasm, Surgical oncology, SAN, Pharmaceutical industry

SAN ANTONIO, May 3, 2024 /PRNewswire/ -- Johnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with ERLEADA® (apalutamide) and androgen deprivation therapy (ADT) in patients with HRLPC who have undergone radical prostatectomy (RP). Following RP, patients who received the treatment regimen showed a 100% biochemical recurrence (BCR)–free rate at 24 months.1 These data were presented today at an Oral Presentation Session (Abstract #P2-07) at the 2024 American Urological Association Annual Meeting AUA, May 3-6, 2024, in San Antonio, Texas. 

Key Points: 
  • SAN ANTONIO, May 3, 2024 /PRNewswire/ -- Johnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with ERLEADA® (apalutamide) and androgen deprivation therapy (ADT) in patients with HRLPC who have undergone radical prostatectomy (RP).
  • * "Results from this study encourage additional research for high-risk localized prostate cancer and highlight the promise of bringing treatment into earlier stages of disease following radical prostatectomy."
  • The study met its primary endpoint, showing that patients who received 12 months of ERLEADA® plus ADT adjuvant to RP experienced no confirmed biochemical recurrence after 12 additional months of follow-up.
  • The treatment regimen demonstrated a serum testosterone recovery (≥150 ng/dL) rate of 76.4% at 12 months (95% CI, 65.0–84.5).

Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032

Retrieved on: 
Friday, May 3, 2024
PFS, United Nations, FDA, Mutation, Daiichi Sankyo, Pancreatic cancer, Bio-Rad Laboratories, MBC, ONC, Prostate cancer, Paper, Behavior, Breast cancer, AstraZeneca, Paclitaxel, Fast track (FDA), Woman, TSX, CELC, DdPCR, Oncolytics Biotech, Ageing, Therapy, Pelareorep, Combination therapy, Combination, Mutant, Survival, Research, Cancer, MRD, Progression-free survival, Marketing, Immunotherapy, AHN, PCR, United, Patient, Type, Pharmaceutical industry

VANCOUVER, BC, May 3, 2024 /PRNewswire/ -- According to a "highly troubling" new study, the rising number of cancer cases in young people is being attributed to "accelerated aging." Further alarm is being spread by the United Nations, whose health authorities are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer, with an additional 4.8 million new cases predicted in 2050. With the global cancer immunotherapy market projected by analysts at Custom Market Insights to reach US$314.4 billion by 2032, growing at a 7.2% CAGR, the biotech sector continues to make significant developments in cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Celcuity Inc. (NASDAQ: CELC), Olema Pharmaceuticals, Inc. (NASDAQ: OLMA), Bio-Rad Laboratories, Inc. (NYSE: BIO), and AstraZeneca PLC (NASDAQ: AZN).

Key Points: 
  • "A key focus for Oncolytics in 2024 is defining the regulatory path for pelareorep in breast cancer treatment," said Matt Coffey, President and CEO of Oncolytics.
  • "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.
  • Oncolytics Biotech requested to meet with the FDA in Q2 2024 to finalize the registrational trial design and objectives for using pelareorep to treat metastatic breast cancer.
  • "These data underscore the potential for treatment with ENHERTU across the spectrum of HR-positive breast cancer, further redefining the treatment of metastatic breast cancer."

Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032

Retrieved on: 
Friday, May 3, 2024
PFS, United Nations, FDA, Mutation, Daiichi Sankyo, Pancreatic cancer, Bio-Rad Laboratories, MBC, ONC, Prostate cancer, Paper, Behavior, Breast cancer, AstraZeneca, Paclitaxel, Fast track (FDA), Woman, TSX, CELC, DdPCR, Oncolytics Biotech, Ageing, Therapy, Pelareorep, Combination therapy, Combination, Mutant, Survival, Research, Cancer, MRD, Progression-free survival, Marketing, Immunotherapy, AHN, PCR, United, Patient, Type, Pharmaceutical industry

VANCOUVER, BC, May 3, 2024 /PRNewswire/ -- According to a "highly troubling" new study, the rising number of cancer cases in young people is being attributed to "accelerated aging." Further alarm is being spread by the United Nations, whose health authorities are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer, with an additional 4.8 million new cases predicted in 2050. With the global cancer immunotherapy market projected by analysts at Custom Market Insights to reach US$314.4 billion by 2032, growing at a 7.2% CAGR, the biotech sector continues to make significant developments in cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Celcuity Inc. (NASDAQ: CELC), Olema Pharmaceuticals, Inc. (NASDAQ: OLMA), Bio-Rad Laboratories, Inc. (NYSE: BIO), and AstraZeneca PLC (NASDAQ: AZN).

Key Points: 
  • "A key focus for Oncolytics in 2024 is defining the regulatory path for pelareorep in breast cancer treatment," said Matt Coffey, President and CEO of Oncolytics.
  • "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.
  • Oncolytics Biotech requested to meet with the FDA in Q2 2024 to finalize the registrational trial design and objectives for using pelareorep to treat metastatic breast cancer.
  • "These data underscore the potential for treatment with ENHERTU across the spectrum of HR-positive breast cancer, further redefining the treatment of metastatic breast cancer."

GT Medical Technologies, Inc. and Theragenics Corporation Forge Distribution Partnership for Cesium-131

Retrieved on: 
Wednesday, May 1, 2024
Medtech, FDA, Radiation, Brachytherapy, Seed, Partnership, Isotopes of caesium, Brain, Prostate cancer, Patient, Neoplasm, Medical imaging

TEMPE, Ariz., May 1, 2024 /PRNewswire/ -- GT Medical Technologies, Inc. (GT MedTech), a medical device company with the mission of improving the lives of patients with brain tumors, today announced it has entered into a strategic distribution partnership with Theragenics Corporation® (Theragenics), a global leader in minimally invasive brachytherapy. The partnership aims to expand physician access to Cesium-131 seeds, offering greater flexibility to support their brachytherapy procedural needs.

Key Points: 
  • TEMPE, Ariz., May 1, 2024 /PRNewswire/ -- GT Medical Technologies, Inc. (GT MedTech), a medical device company with the mission of improving the lives of patients with brain tumors, today announced it has entered into a strategic distribution partnership with Theragenics Corporation® (Theragenics), a global leader in minimally invasive brachytherapy.
  • The partnership aims to expand physician access to Cesium-131 seeds, offering greater flexibility to support their brachytherapy procedural needs.
  • Through the partnership, Theragenics will become the exclusive distributor of Cesium-131 brachytherapy seeds and carriers used for a variety of non-brain cancer related treatments including prostate cancer.
  • Michael Krachon, President of Theragenics Interventional, added, "This partnership reinforces Theragenics' unwavering commitment to brachytherapy.

EQS-News: BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates

Retrieved on: 
Friday, May 3, 2024
USD, Annual, Alnylam Pharmaceuticals, TTR, Federal Reserve, Agios, BB Biotech, Mitapivat, NAV, Esperies, Accounting, Federal, Cardiomyopathy, NBI, Public expenditure, Prostate cancer, Obesity, Environment, DSM-IV codes, ADC, CRISPR, Patient, Thalassemia, Biotechnology, CRISPR Therapeutics, Initial public offering, Beam Therapeutics, Inflation, CHF, IRA, Drug development, Clinical trial, Significance, Therapy, Pharmaceutical industry

BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates

Key Points: 
  • BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates
    The issuer is solely responsible for the content of this announcement.
  • Media release as at April 26, 2024
    Portfolio of BB Biotech AG as at March 31, 2024
    BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates
    Investor sentiment in the biotech space continues to be shaped by the general interest rate environment.
  • Net profit for the first quarter of 2024 amounted to CHF 260 mn (net loss of CHF 254 mn in prior-year quarter).
  • While activity in the secondary market has already picked up, there have been few biotech IPOs so far this year.

Gaxos Health Expands Medical Advisory Board

Retrieved on: 
Thursday, April 25, 2024
Physical medicine and rehabilitation, Johns Hopkins University, Health care, Sport, Abstract, Testosterone, Private practice, MD, Columbia University, PRP, Intelligence, New York (magazine), Prostate cancer, Erectile dysfunction, Cornell University, Drug, Spine, Patient, Bachelor of Arts, Rehabilitation, Public key certificate, Seton Hall University, Medical Center, Hormone replacement therapy, Injury, Partner, Medical device

Roseland, NJ, April 25, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various sectors, today announced that Gaxos Health has expanded its Medical Advisory Board with the appointment of Dr. Eric Margolis and Dr. Jeff Pavell.

Key Points: 
  • Roseland, NJ, April 25, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various sectors, today announced that Gaxos Health has expanded its Medical Advisory Board with the appointment of Dr. Eric Margolis and Dr. Jeff Pavell.
  • “The addition of top medical talent to our Medical Advisory Board reflects our continued commitment to pursuing a best-in-class solution for Gaxos Health,” said Vadim Mats, CEO of Gaxos.AI.
  • “An advisory board of experts in their respective fields will allow to create a better product and advancing our mission of creating value for shareholders.”
    Dr. Eric Margolis, M.D.
  • “We welcome Dr. Margolis and Dr. Pavell to the advisory board as their experience and insight will allow us to create a more fine-tuned solution,” Vadim Mats added.

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology

Retrieved on: 
Wednesday, April 24, 2024
Prostate, Enza, CD46, Prostate cancer, ASCO, Patient, Society, Annual general meeting, SAN

SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that clinical data from the dose escalation portion of the Phase 1b/2 study of FG-3246 in combination with enzalutamide in patients with metastatic castration resistant prostate cancer have been selected for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31-June 4, 2024 in Chicago, Illinois.

Key Points: 
  • SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that clinical data from the dose escalation portion of the Phase 1b/2 study of FG-3246 in combination with enzalutamide in patients with metastatic castration resistant prostate cancer have been selected for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31-June 4, 2024 in Chicago, Illinois.
  • Details for the poster presentation are as follows:
    Session: Poster Session – Genitourinary Cancer – Prostate, Testicular, and Penile
    Title: A Phase 1b dose escalation study of FOR46, a novel antibody-drug conjugate targeting a tumor-specific epitope of CD46, in combination with enzalutamide (Enza) in patients with metastatic castration resistant prostate cancer (mCRPC).

Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024

Retrieved on: 
Tuesday, April 23, 2024
PSMA, Brain, Cancer, Planet, Conference, Webcast, Glioblastoma, Prostate cancer, Indian stock exchange, Patient, Paris Las Vegas

The Company will also host in person one-on-one meetings with investors on Thursday, May 2, 2024.

Key Points: 
  • The Company will also host in person one-on-one meetings with investors on Thursday, May 2, 2024.
  • Conference Location: Paris Hotel & Casino in Las Vegas, NV
    Presentation Webcast: The webcasted presentation can be accessed at https://www.webcaster4.com/Webcast/Page/3026/50183 or on the Company's website at https://shuttlepharma.com/investor-relations/ .
  • 1x1 Meetings: Management will be participating in in-person one-on-one meetings at the event on Thursday, May 2, 2024.
  • To arrange a meeting with management, please contact your Planet MicroCap representative, or Lytham Partners at [email protected] .